...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
【24h】

Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.

机译:新型3,4,5-三甲氧基苄基苯并咪唑衍生物的合成与生物评价,其抑制幽门螺杆菌诱导的人胃上皮细胞发病机病的衍生物。

获取原文
获取原文并翻译 | 示例
           

摘要

Helicobacter pylori infection is associated with gastritis, peptic ulcer, and even gastric malignancy. H.?pylori's antibiotic resistance is the major obstacle preventing its eradication. A series of 3,4,5-trimethoxybenzylbenzimidazole derivatives were synthesized and evaluated for their anti-H. pylori activity. The compound, 2-fluorophenyl-5-methyl-1-(3,4,5-trimethoxybenzyl)benzimidazole (FMTMB), was determined as the most potent in the inhibition of H.?pylori growth and pathogenesis of host cells. An in?vitro H. pylori infection model revealed that FMTMB inhibited H.?pylori adhesion and invasion of gastric epithelial cells. Results from this study provide evidence that FMTMB is a potent therapeutic agent that exhibits both anti-H.?pylori growth properties and anti-H.?pylori-induced pathogenesis of cells.
机译:幽门螺杆菌感染与胃炎,消化性溃疡甚至胃炎有关。 H.?丙氏菌属抗生素抗性是防止其根除的主要障碍。 合成了一系列3,4,5-三甲氧基苄基苯并咪唑衍生物并评价它们的抗H. 幽门活动。 化合物,2-氟苯基-5-甲基-1-(3,4,5-三甲氧基苄基)苯并咪唑(FMTMB)被确定为抑制h.?甲伏氏蛋白生长和宿主细胞的发病机制中最有效的。 in?体外H.幽门螺杆菌感染模型揭示了FMTMB抑制H.?吡咯粘附和胃上皮细胞的侵袭。 本研究的结果提供了FMTMB是一种有效的治疗剂,其表现出抗抗-Myli生长性能和抗-Myli引起的细胞发病机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号